Maritide
Aliases: AMG 133 · GIPR antibody-GLP-1 peptide conjugate
Maritide is a stapled/constrained peptide targeting GLP-1R, GIPR, developed by Amgen for multiple indications. As of Aug 15, 2024, its highest verified stage is Phase 1/2.
Phase 1/2· verified Aug 15, 2024
Identity
- Generic name
- maritide
- Brand names
- —
- Development codes
- AMG 133
- Sponsor / originator
- Amgen
- Route / formulation
- Subcutaneous injection
Development timeline
- Phase 1/2· Obesity· Global
As of Aug 15, 2024 · Confidence: high
Source: A study to evaluate safety, tolerability, PK/PD of AMG 133 in adults with obesityAMG 133 / maritide phase 1 data support monthly dosing; phase 2 initiated.
Trials
View all →| Registry ID | Phase | Status | Enrollment | Completion |
|---|---|---|---|---|
| NCT03548935 | Phase 1 | Completed | 100 | Mar 1, 2023 |
Readouts
View all →Sources
- registryprimary record
A study to evaluate safety, tolerability, PK/PD of AMG 133 in adults with obesity
Amgen Inc. · ClinicalTrials.gov · Apr 4, 2018 · NCT03548935